|
1
|
Kalemkerian GP, Akerley W, Bogner P,
Borghaei H, Chow LQ, Downey RJ, Gandhi L, Ganti AK, Govindan R,
Grecula JC, et al National Comprehensive Cancer Network, : Small
cell lung cancer. J Natl Compr Canc Netw. 11:78–98. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pasche B and Grant SC: Non-small cell lung
cancer and precision medicine: A model for the incorporation of
genomic features into clinical trial design. JAMA. 311:1975–1976.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Saito M, Shiraishi K, Kunitoh H,
Takenoshita S, Yokota J and Kohno T: Gene aberrations for precision
medicine against lung adenocarcinoma. Cancer Sci. 107:713–720.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ding L, Getz G, Wheeler DA, Mardis ER,
McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan
MB, et al: Somatic mutations affect key pathways in lung
adenocarcinoma. Nature. 455:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Weir BA, Woo MS, Getz G, Perner S, Ding L,
Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, et al:
Characterizing the cancer genome in lung adenocarcinoma. Nature.
450:893–898. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
de Mello RA, Madureira P, Carvalho LS,
Araújo A, O'Brien M and Popat S: EGFR and KRAS mutations, and ALK
fusions: Current developments and personalized therapies for
patients with advanced non-small-cell lung cancer.
Pharmacogenomics. 14:1765–1777. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Paul D and Rafael OC: Concurrent
targetable genetic driver alterations in KRAS-mutant lung
adenocarcinoma. Eur J Cancer. 60:e15–e16. 2016. View Article : Google Scholar
|
|
8
|
Nie Q, Yang XN, An SJ, Zhang XC, Yang JJ,
Zhong WZ, Liao RQ, Chen ZH, Su J, Xie Z, et al: CYP1A1*2A
polymorphism as a predictor of clinical outcome in advanced lung
cancer patients treated with EGFR-TKI and its combined effects with
EGFR intron 1 (CA)n polymorphism. Eur J Cancer. 47:1962–1970. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gow CH, Chang HT, Lim CK, Liu CY, Chen JS
and Shih JY: Comparable clinical outcomes in patients with
HER2-mutant and EGFR-mutant lung adenocarcinomas. Genes Chromosomes
Cancer. 56:373–381. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Raponi M, Winkler H and Dracopoli NC: KRAS
mutations predict response to EGFR inhibitors. Curr Opin Pharmacol.
8:413–418. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu C, Zhu J and Zhang X: Network-based
differential gene expression analysis suggests cell cycle related
genes regulated by E2F1 underlie the molecular difference between
smoker and non-smoker lung adenocarcinoma. BMC Bioinformatics.
14:3652013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Andreev K, Trufa ID, Siegemund R, Rieker
R, Hartmann A, Schmidt J, Sirbu H and Finotto S: Impaired
T-bet-pSTAT1α and perforin-mediated immune responses in the tumoral
region of lung adenocarcinoma. Br J Cancer. 113:902–913. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Talhout R, Schulz T, Florek E, van Benthem
J, Wester P and Opperhuizen A: Hazardous compounds in tobacco
smoke. Int J Environ Res Public Health. 8:613–628. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li Y, Xiao X, Ji X, Liu B and Amos CI:
RNA-seq analysis of lung adenocarcinomas reveals different gene
expression profiles between smoking and nonsmoking patients. Tumour
Biol. 36:8993–9003. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chee M, Yang R, Hubbell E, Berno A, Huang
XC, Stern D, Winkler J, Lockhart DJ, Morris MS and Fodor SP:
Accessing genetic information with high-density DNA arrays.
Science. 274:610–614. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Spies M, Dasu MR, Svrakic N, Nesic O,
Barrow RE, Perez-Polo JR and Herndon DN: Gene expression analysis
in burn wounds of rats. Am J Physiol Regul Integr Comp Physiol.
283:R918–R930. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guo QM: DNA microarray and cancer. Curr
Opin Oncol. 15:36–43. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li R, Wang H, Bekele BN, Yin Z, Caraway
NP, Katz RL, Stass SA and Jiang F: Identification of putative
oncogenes in lung adenocarcinoma by a comprehensive functional
genomic approach. Oncogene. 25:2628–2635. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yasrebi H: Comparative study of joint
analysis of microarray gene expression data in survival prediction
and risk assessment of breast cancer patients. Brief Bioinform.
17:771–785. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hong F, Breitling R, McEntee CW, Wittner
BS, Nemhauser JL and Chory J: RankProd: A bioconductor package for
detecting differentially expressed genes in meta-analysis.
Bioinformatics. 22:2825–2827. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hecht SS: Tobacco carcinogens, their
biomarkers and tobacco-induced cancer. Nat Rev Cancer. 3:733–744.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Brüske-Hohlfeld I: Environmental and
occupational risk factors for lung cancer. Methods Mol Biol.
472:3–23. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Taioli E: Gene-environment interaction in
tobacco-related cancers. Carcinogenesis. 29:1467–1474. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chai XM, Li YL, Chen H, Guo SL, Shui LL
and Chen YJ: Cigarette smoke extract alters the cell cycle via the
phospholipid transfer protein/transforming growth
factor-β1/CyclinD1/CDK4 pathway. Eur J Pharmacol. 786:85–93. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Glauert HP, Elliott RS, Han SG, Athey M,
Lee EY and Gairola CG: Effect of cigarette smoke exposure and
mutant Kras overexpression on pancreatic cell proliferation. Oncol
Lett. 13:1939–1943. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jeon SY, Go RE, Heo JR, Kim CW, Hwang KA
and Choi KC: Effects of cigarette smoke extracts on the progression
and metastasis of human ovarian cancer cells via regulating
epithelial-mesenchymal transition. Reprod Toxicol. 65:1–10. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Schmidt U, Wollmann Y, Franke C, Grosse F,
Saluz HP and Hänel F: Characterization of the interaction between
the human DNA topoisomerase IIbeta-binding protein 1 (TopBP1) and
the cell division cycle 45 (Cdc45) protein. Biochem J. 409:169–177.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tercero JA, Longhese MP and Diffley JFX: A
central role for DNA replication forks in checkpoint activation and
response. Mol Cell. 11:1323–1336. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Broderick R, Rainey MD, Santocanale C and
Nasheuer HP: Cell cycle-dependent formation of Cdc45-Claspin
complexes in human cells is compromized by UV-mediated DNA damage.
FEBS J. 280:4888–4902. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Weinstein J: Cell cycle-regulated
expression, phosphorylation, and degradation of p55Cdc. A mammalian
homolog of CDC20/Fizzy/slp1. J Biol Chem. 272:28501–28511. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pollok S, Bauerschmidt C, Sänger J,
Nasheuer HP and Grosse F: Human Cdc45 is a proliferation-associated
antigen. FEBS J. 274:3669–3684. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rahimi H, Ahmadzadeh A, Yousef-amoli S,
Kokabee L, Shokrgozar MA, Mahdian R and Karimipoor M: The
expression pattern of APC2 and APC7 in various cancer cell lines
and AML patients. Adv Med Sci. 60:259–263. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang X, Xiao T, Cheng S, Tong T and Gao
Y: Cigarette smoke suppresses the ubiquitin-dependent degradation
of OLC1. Biochem Biophys Res Commun. 407:753–757. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Borlado LR and Méndez J: CDC6: From DNA
replication to cell cycle checkpoints and oncogenesis.
Carcinogenesis. 29:237–243. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sun T-Y, Xie H-J, Li Z, He H and Kong L-F:
Expression of CDC6 in ovarian cancer and its effect on
proliferation of ovarian cancer cells. Int J Clin Exp Med.
9:10544–10550. 2016.
|
|
36
|
Yun SJ, Kim YH, Kang HW, Kim WT, Kim YJ,
Lee SC, Kim W-J and Kim T: CDC6 mRNA expression is associated with
the aggressiveness of prostate cancer. Eur Urol Suppl.
15:e16252016. View Article : Google Scholar
|
|
37
|
Takabatake N, Toriyama S, Igarashi A,
Tokairin Y, Takeishi Y, Konta T, Inoue S, Abe S, Shibata Y and
Kubota I: A novel polymorphism in CDC6 is associated with the
decline in lung function of ex-smokers in COPD. Biochem Biophys Res
Commun. 381:554–559. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Finetti P, Guille A, Adelaide J, Birnbaum
D, Chaffanet M and Bertucci F: ESPL1 is a candidate oncogene of
luminal B breast cancers. Breast Cancer Res Treat. 147:51–59. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang N and Pati D: Biology and insights
into the role of cohesin protease separase in human malignancies.
Biol Rev Camb Philos Soc. 92:2070–2083. 2017. View Article : Google Scholar : PubMed/NCBI
|
